Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Updates from the German CLL Study Group

Michael Hallek • 28 Aug 2020
SOHO 2020
Chronic Lymphocytic Leukemia Leukemia Chlorambucil Ibrutinib Obinutuzumab Venetoclax
CLL14 CLL17

Michael Hallek, MD, University Hospital of Cologne, Cologne, Germany, updates us on the latest news from the German CLL Study Group including updates from CLL14 (NCT02242942) to be presented at ASH, as well as ongoing trials such as CLL17 (NCT03701282), investigating ibrutinib and obinutuzumab with or without venetoclax. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Michael Hallek

2:24
BCL-2 frontline therapy in CLL
Michael Hallek • 25 Aug 2020
3:02
Treating highly relapsed/refractory CLL
Michael Hallek • 27 Aug 2020
2:32
Value of MRD measurement in CLL
Michael Hallek • 27 Aug 2020
1:17
CLL14: venetoclax-obinutuzumab improves PFS and MRD in untreated, reduced fitness CLL
Michael Hallek • 19 Jun 2019

Related Videos

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals